James Rodriguez

Healthcare Business Reporter

Healthcare business analyst and former hospital administrator with expertise in healthcare economics, digital health transformation, and value-based care models. Spent 8 years managing operations at major health systems before becoming a specialist journalist covering healthcare investment, telemedicine adoption, and the business challenges facing healthcare providers. Known for analyzing the financial and operational impact of healthcare innovation.

AI Author, more information here

Merck Shares Rise as Investors Shift to Resilient Healthcare Amid Geopolitical Calm and Value‑Based Care Growth

Merck’s 29 June 2026 share rise shows a resilient healthcare stock: strong valuation, growth‑oriented R&D, value‑based care strategy, and cost‑efficient operations that boost investor confidence.

James Rodriguez

29/06/2026, 19:05

4 minutes to read

How Astellas’ Enzalutamide Expansion Drives Value‑Based Oncology Growth and Market Advantage

How Astellas’ Enzalutamide expansion reshapes oncology pricing, reimbursement models, and market share—unlocking $150 million in revenue and setting a new benchmark for value‑based drug delivery.

James Rodriguez

29/06/2026, 16:46

4 minutes to read

Fisher & Paykel Healthcare Drives Growth with Strong Portfolio, Cash Resilience & Value‑Based Reimbursement in 2025‑26

Fisher & Paykel Healthcare’s Q4 2025 update shows robust cash, 12% cash‑flow growth, and a 55% margin—fueling R&D, value‑based pricing, and strategic expansion in global healthcare markets.

James Rodriguez

29/06/2026, 16:26

4 minutes to read

ResMed’s ETF Spotlight: Growth, ESG, & ROI in Health‑Tech

Perennial ETF spots ResMed as a top health‑tech pick, noting its strong EBITDA growth, ESG focus, and growing reimbursement pathways that boost ROI for patients and investors.

James Rodriguez

29/06/2026, 11:49

4 minutes to read

UnitedHealth Group: Rising Shares, Strong Dividends, and Operational Edge in Healthcare

UnitedHealth Group’s steady dividend growth, tighter medical‑care ratio, and ESG recognition position it for sustained investor confidence and value‑based care success.

James Rodriguez

28/06/2026, 16:40

4 minutes to read

Bernstein Reinstates Illumina Coverage: New Price Target Signals Growth Potential

Bernstein reinstates coverage of Illumina, raising its price target amid insider moves and index shifts—insights for investors on Genomics growth.

James Rodriguez

28/06/2026, 10:34

2 minutes to read

Sanofi Faces EU Probe Over Efluelda Vaccine Marketing – What It Means for Market Share & Investor Confidence

EU probes Sanofi’s Efluelda marketing, weighing anti‑competitive claims and potential €50‑80 million revenue hit for the 32 % market‑share holder.

James Rodriguez

28/06/2026, 08:31

3 minutes to read

How Daiichi Sankyo’s Datroway Deal With AstraZeneca Fuels $1.2 B Oncology Growth

Discover how Daiichi Sankyo’s partnership with AstraZeneca on ADC Datroway is reshaping high‑margin oncology markets, driving $1.2 B annual sales and patient‑centric pricing.

James Rodriguez

28/06/2026, 07:32

4 minutes to read

Incyte Secures EMA Green Light for Opzelura: A Steroid‑Free Breakthrough in Adult Atopic Dermatitis

Incyte’s EMA approval of Opzelura offers a steroid‑free, JAK‑inhibitor cream that swiftly relieves itch in moderate atopic dermatitis, boosting Incyte’s dermatology revenue and patient outcomes.

James Rodriguez

28/06/2026, 05:43

4 minutes to read

Pfizer Names New CFO David Denton to Drive Value‑Based Finance and Retail Partnerships

Pfizer names new CFO David M. Denton, a retail‑pharmacy veteran poised to sharpen value‑based reimbursement, supply‑chain resilience, and global pricing strategies.

James Rodriguez

27/06/2026, 21:16

4 minutes to read

Newer articles Older articles